What is Roth Capital’s Estimate for MBRX FY2029 Earnings?

Posted by Defense World Staff on Jan 13th, 2025

Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) – Roth Capital issued their FY2029 EPS estimates for Moleculin Biotech in a report issued on Thursday, January 9th. Roth Capital analyst J. Aschoff anticipates that the company will post earnings per share of $2.81 for the year. The consensus estimate for Moleculin Biotech’s current full-year earnings is ($7.98) per share.

Several other equities research analysts have also commented on the company. Maxim Group dropped their price target on Moleculin Biotech from $20.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, November 12th. StockNews.com assumed coverage on Moleculin Biotech in a report on Wednesday, January 8th. They set a “sell” rating for the company.

Check Out Our Latest Research Report on MBRX

Moleculin Biotech Stock Performance

MBRX stock opened at $1.64 on Monday. Moleculin Biotech has a 52 week low of $1.50 and a 52 week high of $11.17. The business has a fifty day simple moving average of $2.27 and a 200-day simple moving average of $2.62.

Institutional Investors Weigh In On Moleculin Biotech

A hedge fund recently raised its stake in Moleculin Biotech stock. Armistice Capital LLC boosted its stake in Moleculin Biotech, Inc. (NASDAQ:MBRX – Free Report) by 5.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 156,000 shares of the company’s stock after acquiring an additional 7,505 shares during the quarter. Armistice Capital LLC owned about 6.75% of Moleculin Biotech worth $549,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Moleculin Biotech Company Profile

(Get Free Report)

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.